| 5.1 0.18 (3.66%) | 11-28 13:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 6.41  |
1-year : | 7.48 |
| Resists | First : | 5.48 |
Second : | 6.41 |
| Pivot price | 3.3 |
|||
| Supports | First : | 3.26 |
Second : | 1.88 |
| MAs | MA(5) : | 4.54 |
MA(20) : | 2.97 |
| MA(100) : | 2.5 |
MA(250) : | 2.74  |
|
| MACD | MACD : | 0.6 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 93.3 |
D(3) : | 92.3 |
| RSI | RSI(14): 87.6 |
|||
| 52-week | High : | 7.38 | Low : | 1.11 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ANVS ] has closed below upper band by 7.8%. Bollinger Bands are 459.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.23 - 5.25 | 5.25 - 5.27 |
| Low: | 4.52 - 4.54 | 4.54 - 4.57 |
| Close: | 4.88 - 4.92 | 4.92 - 4.95 |
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Sat, 29 Nov 2025
Certain Warrants of Annovis Bio, Inc. are subject to a Lock-Up Agreement Ending on 30-NOV-2025. - MarketScreener
Mon, 24 Nov 2025
Annovis Announces Two Presentations at the CTAD 2025 Conference - GlobeNewswire
Mon, 17 Nov 2025
Annovis Bio, Inc. (ANVS) Stock: Surges on Breakthrough Data in Alzheimer’s and Parkinson’s Disease Treatment - parameter.io
Mon, 17 Nov 2025
Annovis Bio Stock Jumps On Heels Of New Parkinson's Data - Annovis Bio (NYSE:ANVS) - Benzinga
Wed, 12 Nov 2025
Annovis Bio Inc. Reports Q3 2025 Financial Results - TipRanks
Thu, 06 Nov 2025
Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer’s Program - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 27 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 15 (%) |
| Held by Institutions | 11.3 (%) |
| Shares Short | 1,030 (K) |
| Shares Short P.Month | 1,400 (K) |
| EPS | -1.43 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.67 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -105.9 % |
| Return on Equity (ttm) | -246.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -3.57 |
| PEG Ratio | 0 |
| Price to Book value | 7.61 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|